Weber Kristy L., Doucet Michele, Price Janet E. Renal Cell Carcinoma Bone Metastasis: Epidermal Growth Factor Receptor Targeting. Clinical Orthopaedics and Related Research. 2003;415:S86-S94. doi:10.1097/01.blo.0000093050.96273.35.
Abstract
Renal cell carcinoma frequently metastasizes to the skeleton in the later stages of the disease. Patients with bone metastasis from renal cell carcinoma experience severe pain, neurologic compromise, and frequent pathologic fractures. These tumors are relatively resistant to chemotherapy and radiation, and the 5-year survival of patients is less than 10%. The epidermal growth factor receptor is overexpressed in human renal cell carcinoma and hypothesized to be a potential target in the treatment of bone metastasis. Using in vitro studies, it was shown that blockade of the epidermal growth factor receptor was effective in decreasing proliferation and receptor autophosphorylation of a human bone-derived renal cell carcinoma cell line. In an experimental nude mouse model, treatment with Taxol and protein tyrosine kinase inhibitor 166, a small molecule receptor tyrosine kinase inhibitor, blocked the growth of renal cell carcinoma in the tibia and resulted in decreased bone destruction. The use of protein tyrosine kinase inhibitor 166 and Taxol was cytostatic and nontoxic in long-term animal experiments. Epidermal growth factor receptor blockade is an exciting potential therapy for renal cell carcinoma bone metastasis in humans, but because it is cytostatic rather than cytotoxic, its optimal role may be as a supplement to cytotoxic chemotherapy. It ultimate role and its relationship to other therapeutic interventions remains to be elucidated and validated.
Last Updated on September 29, 2026
🔗 Knowledge Graph & Clinical Correlates
OrthopaedicsOne Living Semantic Network🛠️ Operative Techniques
- Triple innominate osteotomy Hip and Knee
- Total scapular resections with endoprosthetic reconstruction Musculoskeletal Tumor
🩺 Clinical Conditions & Indications
- Who should undergo biopsy of a bone lesion Patient selection for a biopsy is important: It is intended to confirm the radiologic diagnosis in patients with...
- Who should do the biopsy of a bone lesion Clinical studies undertaken by the Musculoskeletal Tumor Society have documented a high incidence of problems suffered by patients...
- Where is the lesion Original Clinical Contribution: Authored for the OrthopaedicsOne Musculoskeletal Oncology Specialty Section. Preserved, digitized, and updated to modern evidence-based...
- What is the lesion doing to the bone Bone tumors have a limited number of potential effects on the skeleton. The most common is to produce...
🔬 Anatomy, Pathology & Diagnostics
- What Are the Factors Associated with Acetabular Correction in Perthes-like Hip Deformities Pelvis and Acetabulum
- Venography Pelvis and Acetabulum
- Validation of cDNA Microarray Analysis to Distinguish Tumor Type Ex Vivo Generalized Bone and Joint
- Urokinase Plasminogen Activator System – A Multifunction Role in Tumour Progression and Metastasis Pelvis and Acetabulum